
BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris
About this episode
Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.
Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
BMS Chooses Houston for $2.3B Manufacturing Facility
By Alex Philippidis, GEN Edge, Aug 10, 2026
Next 10 U.S. Biopharma Clusters
By Alex Philippidis, GEN, Aug 12, 2026
Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map
By Alex Philippidis, GEN Edge, Aug 5, 2026
COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID
GEN, Aug 5, 2026
Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained
By Alex Philippidis, GEN, Oct 5, 2020
Lessons from the COVID Crisis: An Interview with Peter Hotez
By Alex Philippidis, GEN Edge, Oct 19, 2022
How to Conquer Coronavirus: Top 35 Treatments in Development
By Alex Philippidis, GEN, March 2, 2020
Candida auris Persists in Hair Follicles, Hijacks Immune Signaling
GEN, August 10, 2026
September 23, 2026
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
The State of Biologics Testing 2026
Charles River Laboratories and GEN, June 10, 2026
Subscribe to GEN’s newsletters
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Touching Base publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Touching Base

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntingt...
Touching Base

Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
Touching Base

Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Di...
Touching Base

Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccin...
Touching Base